Background on Dr Vinay Prasad
Dr Vinay Prasad, a prominent figure in the field of medicine, held the position of Chief Medical and Scientific Officer at the Food and Drug Administration (FDA). His tenure came to an end on 29 July 2025, following a series of controversies that sparked significant debate. Prasad’s resignation was confirmed by the Department of Health and Human Services (HHS), marking the end of a brief but impactful period in his career within the federal agency.
Prasad’s decision to step down was reportedly influenced by his desire to spend more time with family and avoid becoming a distraction for the FDA. His departure followed a period of intense scrutiny over key regulatory decisions and growing pressure from various political figures. The circumstances surrounding his resignation have raised questions about the stability and direction of the FDA during this time.
Who Is Dr Vinay Prasad?
Dr Vinay Prasad is a haematologist-oncologist, epidemiologist, and academic known for his strong advocacy for evidence-based medicine. With over 450 peer-reviewed publications, he has gained recognition for his critical analyses of the FDA’s drug approval processes and health policies implemented during the pandemic.
In May 2025, Prasad was appointed as Director of the FDA’s Center for Biologics Evaluation and Research (CBER). Shortly after, he was promoted to Chief Medical and Scientific Officer, serving as the top adviser to FDA Commissioner Marty Makary. His appointment was viewed as an effort to enhance regulatory standards across vaccines, biologics, and gene therapies.
Vaccine Rulings and Public Backlash
One of the most contentious decisions made by Prasad involved the restriction of Moderna and Novavax’s updated COVID-19 vaccines. Under his guidance, these vaccines were authorised only for individuals aged 65 and older or those with weakened immune systems. This ruling led to immediate concerns from within the agency and attracted criticism from political commentators who saw the restrictions as overly cautious.
Critics argued that the policy undermined public health messaging and eroded confidence in the consistency of the FDA. The decision highlighted the challenges faced by the agency in balancing scientific caution with public health needs.
Gene Therapy Controversy
The controversy surrounding Prasad’s leadership escalated following the FDA’s handling of Elevidys, a gene therapy developed by Sarepta Therapeutics for Duchenne muscular dystrophy. After reports of patient deaths, the FDA temporarily paused distribution of the treatment. However, the agency later reversed its decision and resumed authorisation shortly before Prasad’s resignation.
This back-and-forth raised questions about internal coordination and risk communication. The reversal created confusion among physicians and families seeking clarity on treatment safety. While no direct blame was placed on Prasad, the incident contributed to the perception of instability under his leadership.
Political and Ideological Pressures
Prasad also became a focal point for political criticism. Right-leaning activists and commentators accused him of holding progressive views that conflicted with the Trump administration’s direction. Media figures such as Laura Loomer labelled him a “progressive leftist saboteur,” while The Wall Street Journal published an editorial calling him “a Bernie Sanders acolyte in MAHA drag.”
The ideological divide placed the FDA in a difficult position, as scientific caution clashed with political expectations. This tension underscored the challenges faced by the agency in navigating complex regulatory decisions amid a polarised environment.
Resignation and Uncertain Future
Andrew Nixon, a spokesperson for the Department of Health and Human Services, confirmed Prasad’s resignation. He stated, “Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California to be with his family.”
Commissioner Marty Makary has yet to announce a replacement for Prasad. The future of the FDA remains uncertain as the agency navigates the challenges of leadership transitions and continues to address pressing public health issues.
Comment